PT - JOURNAL ARTICLE AU - Patrícia D. Deps AU - Taynah A. R. Repsold AU - Claudio G. Salgado AU - Raquel de Carvalho Bouth AU - Selma Regina Penha Silva Cerqueira AU - Marisa Simon Brezinscki AU - Rebeca Ruppert Galarda Baptista Peixoto AU - Jaison Antonio Barreto AU - Andrea M. A. Fonseca AU - Marlene L. S. Peixoto AU - Seyna Ueno R. Mendes AU - Rafael Pereira Rabelo Mendes AU - Pedro Paulo dos Santos Oliveira AU - Ciro Martins Gomes TI - COVID-19 in persons affected by Hansen’s disease in Brazil AID - 10.1101/2020.12.11.20247262 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.11.20247262 4099 - http://medrxiv.org/content/early/2020/12/14/2020.12.11.20247262.short 4100 - http://medrxiv.org/content/early/2020/12/14/2020.12.11.20247262.full AB - Background Hansen’s disease (HD) is endemic in Brazil, a country with the third highest number of COVID-19 cases in the world and the second highest number of COVID-19 deaths. COVID-19 in persons affected by HD has not been described at population level in this country.Methods We collated numbers of COVID-19 cases and deaths among patients who were receiving routine treatment for HD at six centres across Brazil (Belém, Bauru, Brasília, Vitória, Petrolina, Palmas) between 1st March and 10th December 2020.Results Of 1,333 HD patients receiving treatment, 70 (5.2%) reported having had COVID-19. Almost all patients (97% (1,296/1,333)) including all but one of the COVID-19 cases were receiving MDT comprising rifampicin (600mg once per month), dapsone (100mg daily), and clofazimine (50 mg daily plus 300 mg once per month). Four patients died, including a patient in their 30’s on MDT who had a severe type 2 HD reaction (erythema nodosum leprosum) and who was taking clofazimine 100mg daily.Conclusions We cannot determine from these preliminary data whether persons affected by Hansen’s disease have a higher or lower risk of COVID-19 and related mortality compared with the general population. We will continue to monitor the effects of COVID-19 in persons affected by and treated for HD and extend this to monitor SARS-CoV-2 vaccine effectiveness in this group of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received no specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the research ethics committee (Comitê de Ética em Pesquisa, CEP) of the Universidade Federal do Espírito Santo (UFES), certificate no. 40347520.5.0000.5060.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available by request to the corresponding author.